104 related articles for article (PubMed ID: 25311563)
1. Synthesis and highly potent hypolipidemic activity of alpha-asarone- and fibrate-based 2-acyl and 2-alkyl phenols as HMG-CoA reductase inhibitors.
Mendieta A; Jiménez F; Garduño-Siciliano L; Mojica-Villegas A; Rosales-Acosta B; Villa-Tanaca L; Chamorro-Cevallos G; Medina-Franco JL; Meurice N; Gutiérrez RU; Montiel LE; Cruz Mdel C; Tamariz J
Bioorg Med Chem; 2014 Nov; 22(21):5871-82. PubMed ID: 25311563
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and docking of highly hypolipidemic agents: Schizosaccharomyces pombe as a new model for evaluating alpha-asarone-based HMG-CoA reductase inhibitors.
Argüelles N; Sánchez-Sandoval E; Mendieta A; Villa-Tanaca L; Garduño-Siciliano L; Jiménez F; Cruz Mdel C; Medina-Franco JL; Chamorro-Cevallos G; Tamariz J
Bioorg Med Chem; 2010 Jun; 18(12):4238-48. PubMed ID: 20576575
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking of the highly hypolipidemic agent alpha-asarone with the catalytic portion of HMG-CoA reductase.
Medina-Franco JL; López-Vallejo F; Rodríguez-Morales S; Castillo R; Chamorro G; Tamariz J
Bioorg Med Chem Lett; 2005 Feb; 15(4):989-94. PubMed ID: 15686898
[TBL] [Abstract][Full Text] [Related]
4. Antihyperlipidemic studies of newly synthesized phenolic derivatives: in silico and in vivo approaches.
Aqeel MT; Ur-Rahman N; Khan AU; Ashraf Z; Latif M; Rafique H; Rasheed U
Drug Des Devel Ther; 2018; 12():2443-2453. PubMed ID: 30127594
[TBL] [Abstract][Full Text] [Related]
5. Bioactivity guided fractionation and hypolipidemic property of a novel HMG-CoA reductase inhibitor from Ficus virens Ait.
Iqbal D; Khan MS; Khan MS; Ahmad S; Hussain MS; Ali M
Lipids Health Dis; 2015 Mar; 14():15. PubMed ID: 25884722
[TBL] [Abstract][Full Text] [Related]
6. Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking.
Islam B; Sharma C; Adem A; Aburawi E; Ojha S
Drug Des Devel Ther; 2015; 9():4943-51. PubMed ID: 26357462
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of HMG-CoA Reductase: Current and Future Prospects.
Singh N; Tamariz J; Chamorro G; Medina-Franco JL
Mini Rev Med Chem; 2009 Oct; 9(11):1272-83. PubMed ID: 19929805
[TBL] [Abstract][Full Text] [Related]
8. Structural mechanism for statin inhibition of HMG-CoA reductase.
Istvan ES; Deisenhofer J
Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
[TBL] [Abstract][Full Text] [Related]
9. Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening.
Lin SH; Huang KJ; Weng CF; Shiuan D
Drug Des Devel Ther; 2015; 9():3313-24. PubMed ID: 26170618
[TBL] [Abstract][Full Text] [Related]
10. Alpha-asarone inhibits HMG-CoA reductase, lowers serum LDL-cholesterol levels and reduces biliary CSI in hypercholesterolemic rats.
Rodríguez-Páez L; Juárez-Sanchez M; Antúnez-Solís J; Baeza I; Wong C
Phytomedicine; 2003; 10(5):397-404. PubMed ID: 12834005
[TBL] [Abstract][Full Text] [Related]
11. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
12. IAF, QGF, and QDF Peptides Exhibit Cholesterol-Lowering Activity through a Statin-like HMG-CoA Reductase Regulation Mechanism: In Silico and In Vitro Approach.
Silva M; Philadelpho B; Santos J; Souza V; Souza C; Santiago V; Silva J; Souza C; Azeredo F; Castilho M; Cilli E; Ferreira E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681729
[TBL] [Abstract][Full Text] [Related]
13. 2,4,5-trimethoxycinnamic acid: the major metabolite of alpha-asarone, retains most of the pharmacological properties of alpha-asarone.
Antunez-Solis J; Hernández-Derramadero F; Aquino-Vega M; Ibarra-Ramírez S; Rodríguez-Páez L; Baeza I; Wong C
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):903-9. PubMed ID: 18686138
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
Bratton LD; Auerbach B; Choi C; Dillon L; Hanselman JC; Larsen SD; Lu G; Olsen K; Pfefferkorn JA; Robertson A; Sekerke C; Trivedi BK; Unangst PC
Bioorg Med Chem; 2007 Aug; 15(16):5576-89. PubMed ID: 17560788
[TBL] [Abstract][Full Text] [Related]
15. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
Liang K; Kim CH; Vaziri ND
Am J Physiol Renal Physiol; 2005 Mar; 288(3):F539-44. PubMed ID: 15507547
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of recombinant enzyme 3-hydroxy-3-methylglutaryl-CoA reductase from Candida glabrata by α-asarone-based synthetic compounds as antifungal agents.
Andrade-Pavón D; Ortiz-Álvarez J; Sánchez-Sandoval E; Tamariz J; Hernández-Rodríguez C; Ibarra JA; Villa-Tanaca L
J Biotechnol; 2019 Feb; 292():64-67. PubMed ID: 30690093
[TBL] [Abstract][Full Text] [Related]
17. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
[TBL] [Abstract][Full Text] [Related]
18. Molecular Docking, Synthesis And Biological Evaluation Of Ergosteryl-Ferulate As A Hmg-Coa Reductase Inhibitor.
Aziz S; Elfahmi -; Soemardji AA; Sukrasno -
Pak J Pharm Sci; 2020 May; 33(3):997-1003. PubMed ID: 33191223
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new druggable sites in the anti-cholesterol target HMG-CoA reductase by computational alanine scanning mutagenesis.
Gesto DS; Cerqueira NM; Ramos MJ; Fernandes PA
J Mol Model; 2014 Apr; 20(4):2178. PubMed ID: 24671303
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and hypolipidemic activity of modified side chain alpha-asarone homologues.
Cruz A; Garduño L; Salazar M; Martínez E; Jiménez-Vázquez HA; Díaz F; Chamorro G; Tamariz J
Arzneimittelforschung; 2001; 51(7):535-44. PubMed ID: 11505784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
